Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment

Molecular Immunology

Volumn 45, Issue 15, 2008, Pages 3878-3888

  Atassi, M Zouhair ^a   Dolimbek, Behzod Z ^a   Jankovic, Joseph ^a   Steward, Lance E ^b   Aoki, K Roger ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b ALLERGAN INC   (United States)

Author keywords

Antigenic sites; Blocking antibodies; Botulinum neurotoxin A; Botulinum neurotoxin B; Cervical dystonia; Epitopes; Immunoresistance; Synthetic peptides

Indexed keywords

BLOCKING ANTIBODY; BOTULINUM TOXIN A; BOTULINUM TOXIN B; EPITOPE;

ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; CERVICAL DYSTONIA; CLINICAL ARTICLE; CONTROLLED STUDY; DYSTONIA; ELECTRIC POTENTIAL; GENETIC REGULATION; HEAVY CHAIN; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; IMMUNE RESPONSE; IMMUNITY; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TEMPERATURE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, BLOCKING; BINDING SITES, ANTIBODY; BOTULINUM TOXINS; DRUG RESISTANCE; EPITOPES; HUMANS; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PEPTIDE MAPPING; PEPTIDES; PROTEIN BINDING; TORTICOLLIS;

MUS;

EID: 49449089672     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2008.06.031     Document Type: Article

References (51)

1. Atassi M.Z. Antigenic structure of myoglobin. The complete immunochemical anatomy of a protein and conclusions relating to antigenic structures of proteins. Immunochem. 12 (1975) 423-438
2. Atassi M.Z. Antigenic structures of proteins. Their determination has revealed important aspects of immune recognition and generated strategies for synthetic mimicking or protein binding sites. Europ. J. Biochem. 145 (1984) 1-20
3. Atassi M.Z. Basic immunological aspects of botulinum toxin therapy. Mov. Disord. 19 Suppl. 8 (2004) S68-S84
4. Atassi M.Z., and Oshima M. Structure, activity and immune (T and B Cell) recognition of botulinum neurotoxin. Crit. Rev. Immunol. 19 (1999) 219-260
5. Atassi M.Z., and Smith J.A. A Proposal for the nomenclature of antigen sites in peptides and proteins. Immunochem. 15 (1978) 609-610
6. Atassi M.Z., Dolimbek B.Z., and Manshouri T. Antibody and T-cell recognition of (-bungarotoxin and its synthetic loop peptides. Mol. Immunol. 13 (1995) 927-932
7. Atassi M.Z., Dolimbek G.S., Deitiker P.R., Aoki K.R., and Dolimbek B.Z. Submolecular recognition profiles in two mouse strains of non-protective and protective antibodies against botulinum neurotoxin A. Mol. Immunol. 42 (2005) 1509-1520
8. Atassi M.Z., Manshouri T., and Sakata S. Localization and synthesis of the hormone-binding regions of the human thyrotropin receptor. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 3613-3617
9. Atassi M.Z. On the enhancement of anti-neurotoxin antibody production by subcomponents HA1 and HA3b of Clostridium botulinum type B 16S toxin-haemagglutinin. Microbiology 52 (2006) 1891-1895
10. Bandyopadhyay S., Clark A.W., Das Gupta B., and Sathyamoorthy V. Role of the heavy and light chains of botulinum neurotoxin in neuromuscular paralysis. J. Biol. Chem. 262 (1987) 2660-2663
11. Binder W.J., Brin M.F., Blitzer A., and Pogoda J.M. Botulinum toxin type A (BOTOX) for treatment of migraine. Dis. Mon. 48 (2002) 323-335
12. Byrne M.P., and Smith L.A. Development of vaccines for prevention of botulism. Biochimie 82 (2000) 955-966
13. Campbell, K.D., Collins, M.D., East A.K., 1993. Gene probes for identification of the botulinal neurotoxin gene and specific identification of neurotoxin types B, E, and F. J. Clin. Microbiol. 31, 2255-2262. Also, B3: C. botulinum (strain non-proteolytic Eklund 2B) gene for neurotoxin type B. Accession # X70819. (Ref. same as B2); B4: C. botulinum (strain proteolytic B) gene for neurotoxin type B. Accession # X70817. (Ref. same as B2); B5: Clostridium botulinum neurotoxin type B (botB) gene, complete cds Accession # M81186.
14. Chai Q., Arndt J.W., Dong M., Tepp W.H., Johnson E.A., Chapman E.R., and Stevens R.C. Structural basis of cell surface receptor recognition by botulinum neurotoxin B. Nature 444 (2006) 1096-1100
15. Diamond A., and Jankovic J. Botulinum toxin in dermatology-beyond wrinkles and sweat. J. Cosmet. Dermatol. 5 (2006) 169
16. David C.S., and Atassi M.Z. Genetic control and intersite influences on the immune response to sperm whale myoglobin. Advan. Exp. Med. Biol. 150 (1982) 97-126
17. Dolimbek B.Z., Jankovic J., and Atassi M.Z. Cross-reaction of tetanus and Botulinum neurotoxins A and B and the boosting effect of Botulinum neurotoxins A and B on a primary anti-tetanus antibody response. Immunol. Invest. 31 (2002) 247-262
18. Dolimbek B.Z., and Atassi M.Z. α-Bungarotoxin peptides afford a synthetic vaccine against toxin poisoning. J. Prot. Chem. 13 (1994) 490-493
19. Dolimbek B.Z., and Atassi M.Z. Protection against (-bungarotoxin poisoning by immunization with synthetic toxin peptides. Mol. Immunol. 33 (1996) 681-689
20. Dolimbek B.Z., Aoki K.R., Steward L.E., Jankovic J., and Atassi M.Z. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol. Immunol. 44 (2007) 1029-1041 Epub 2006 May 2
21. Dolimbek B.Z., Steward L.E., Aoki K.R., and Atassi M.Z. Immune recognition of botulinum neurotoxin B: antibody-binding regions on the heavy chain of the toxin. Mol. Immunol. 45 (2008) 910-924 Epub 2007 Sep 25
22. Dolimbek G.S., Dolimbek B.Z., Aoki K.R., and Atassi M.Z. Mapping of the antibody and T cell recognition profiles of the HN domain (residues 449-859) of the heavy chain of botulinum neurotoxin A in two high-responder mouse strains. Immunol. Invest. 34 (2005) 119-142
23. Dong M., Yeh F., Tepp W.H., Dean C., Johnson E.A., Janz R., and Chapman E.R. SV2 Is the protein receptor for botulinum neurotoxin A. Science 312 (2006) 592-596
24. Fu F.N., Lomneth R.B., Cai S., and Singh B.R. Role of zinc in the structure and toxic activity of botulinum neurotoxin. Biochemistry 37 (1998) 5267-5278
25. Garcia-Rodriguez C., Levy R., Arndt J.W., Forsyth C.M., Razai A., Lou J., Geren I., Stevens R.C., and Marks J.D. Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum Neurotoxin. Nature Biotechnol. 25 (2007) 107-116
26. Göschel H., Wohlfarth K., Frevert J., Dengler R., and Bigalke H. Botulinum A toxin therapy: neutralizing and nonneutralizing Abs-therapeutic consequences. Exp. Neurol. 147 (1997) 96-102
27. Gui D., Rossi S., Runfola M., and Magalini S.C. Review article: botulinum toxin in the therapy of gastrointestinal motility disorders. Aliment. Pharmacol. Ther. 18 (2003) 1-16
28. Hutson R.A., Collins M.D., East A.K., and Thompson D.E. Nucleotide sequence of the gene coding for non-proteolytic Clostridium botulinum type B neurotoxin: comparison with other clostridial neurotoxins. Curr. Microbiol. 28 (1994) 101-110
29. Jankovic J. Treatment of cervical dystonia with botulinum toxin. Mov. Disord. 19 Suppl. 8 (2004) S109-S115
30. Jankovic J. Treatment of dystonia. Lancet Neurol. 5 (2006) 864-872
31. Jankovic J., Hunter C., Dolimbek B.Z., Dolimbek G.S., Adler C.H., Brashear A., Comella C.L., Gordon M., Riley D.E., Sethi K., Singer C., Stacy M., Tarsy D., and Atassi M.Z. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology 67 (2006) 2233-2235
32. Jin R., Rummel A., Binz T., and Brunger A.T. Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity. Nature 444 (2006) 1092-1095
33. Kazim A.L., and Atassi M.Z. A novel and comprehensive synthetic approach for the elucidation of protein antigenic structures. Determination of the full antigenic profile of the alpha-chain of human haemoglobin. Biochem. J. 191 (1980) 261-264
34. Kazim A.L., and Atassi M.Z. Structurally inherent antigenic sites. Localization of the antigenic sites of the alpha-chain of human haemoglobin in three host species by a comprehensive synthetic approach. Biochem. J. 203 (1982) 201-208
35. Kazim A.L., and Atassi M.Z. Prediction and confirmation by synthesis of two antigenic sites in human haemoglobin by extrapolation from the known antigenic structure of sperm whale myoglobin. Biochem. J. 167 (1977) 275-278
36. Kozaki S., Miki A., Kamata Y., Ogasawara J., and Sakaguchi G. Immunological characterization of papain-induced fragments of Clostridium botulinum type A neurotoxin and interaction of the fragments with brain synaptosomes. Infect. Immun. 57 (1989) 2634-2639
37. Lacy D.B., Tepp W., Cohen A.C., DasGupta B.R., and Stevens R.C. Crystal structure of Botulinum neurotoxin type A and implications for toxicity. Nat. Struct. Biol. 5 (1998) 898-902
38. Li L., and Singh B.R. In vitro translation of type A Clostridium botulinum neurotoxin heavy chain and analysis of its binding to rat synaptosomes. J. Prot. Chem. 18 (1999) 89-95
39. Mahrhold S., Rummel A., Bigalke H., Davletov B., and Binz T. The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett. 580 (2006) 2011-2014
40. Maruta T., Dolimbek B.Z., Aoki K.R., and Atassi M.Z. Inhibition by human sera of botulinum neurotoxin-A binding to synaptosomes: a new assay for blocking and non-blocking antibodies. J. Neurosci. Methods 151 (2006) 90-96
41. Maruta T., Dolimbek B.Z., Aoki K.R., Steward L.E., and Atassi M.Z. Mapping of the synaptosome-binding regions on the heavy chain of botulinum neurotoxin A by synthetic overlapping peptides encompassing the entire chain. Protein J. 23 (2004) 539-552
42. Nishiki T., Tokuyama Y., Kamata Y., Nemoto Y., Yoshida A., Sekiguchi M., Takahashi M., and Kozaki S. Binding of botulinum type B neurotoxin to Chinese hamster ovary cells transfected with rat synaptotagmin II cDNA. Neurosci. Lett. 208 (1996) 105-108
43. Nishiki T., Tokuyama Y., Kamata Y., Nemoto Y., Yoshida A., Sato K., Sekiguchi M., Takahashi M., and Kozaki S. The high-affinity binding of Clostridium botulinum type B neurotoxin to synaptotagmin II associated with gangliosides GT1b/GD1a. FEBS Lett. 378 (1996) 253-257
44. Okuda K., Christadoss P.R., Twining S.S., Atassi M.Z., and David C.S. Genetic control of immune response to sperm whale myoglobin in mice. I. T lymphocyte proliferative response under H-2-linked Ir gene control. J. Immunol. 121 (1978) 866-868
45. Okuda K., Sakata S., Atassi M.Z., and David C.S. Genetic control of the immune response to hen's egg-white lysozyme in mice. I. Antibody and T-lymphocyte proliferative responses to the native protein. J. Immunogenet. 6 (1979) 447-652
46. Okuda K., Twining S.S., David C.S., and Atassi M.Z. Genetic control of immune response to sperm whale myoglobin in mice. II. T lymphocyte proliferative response to the synthetic antigenic sites. J. Immunol. 123 (1979) 182-188
47. Schiavo G., Rossetto O., Santucci A., DasGupta B.R., and Montecucco C. Botulinum neurotoxins are zinc proteins. J. Biol. Chem. 267 (1992) 23479-23483
48. Simpson L.L. Molecular pharmacology of botulinum toxin and tetanus toxin. Ann. Rev. Pharmacol. Toxicol. 26 (1986) 427-453
49. Swaminathan S., and Eswaramoorthy S. Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat. Struct. Biol. 7 (2000) 693-699
50. Turton K., Chaddock J.A., and Acharya K.R. Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends. Biochem. Sci. 27 (2002) 552-558
51. Yoshioka N., and Atassi M.Z. Antigenic structure of human haemoglobin: localization of the antigenic sites of the β-chain in three host species by synthetic overlapping peptides representing the entire chain. Biochem. J. 234 (1986) 441-447